- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Androgen Therapy, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2039
- U.S. locations
- 214
- States / cities
- Tucson, Arizona • Dublin, California • Fremont, California + 172 more
Location Directory
Clinical trials in Aurora, Colorado
This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2167
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 385–396 of 2,167 matching trials in Aurora, CO.
Indexed local directory records.
Institutions in Aurora
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Stored official records
Open in full search- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Azacitidine (AZA), Bleximenib, Placebo, Venetoclax (VEN)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
- Conditions
- Colorectal Neoplasms
- Interventions
- 5-fluorouracil, Amivantamab, Bevacizumab, Cetuximab, Irinotecan, Leucovorin calcium/Levoleucovorin
- Drug · Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 71
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more
- Conditions
- Colorectal Neoplasms, Gastrointestinal Neoplasms
- Interventions
- Bevacizumab, FOLFIRI, FOLFOX, JNJ-89402638
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, MRI, Pembrolizumab, Questionnaire Administration, Tivozanib
- Procedure · Biological · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 429
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin (PLD), Rina-S, Topotecan
- Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 72
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
- Conditions
- Angelman Syndrome
- Interventions
- GTX-102, Sham-LP
- Drug · Procedure
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more
- Conditions
- Thrombocytopenia, Neonatal Alloimmune
- Interventions
- Intravenous immunoglobulins (IVIG), Nipocalimab, Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 13 more
- Conditions
- HIV-1
- Interventions
- PGT121.414.LS, VRC07-523LS
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 72 Hours
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Aurora, Colorado • Jacksonville, Florida + 7 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Amivantamab, Carboplatin, Paclitaxel, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 15
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
- Conditions
- Non-Muscle Invasive Bladder Neoplasms
- Interventions
- Gemcitabine, MMC, TAR-210
- Drug · Combination Product
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Apalutamide, JNJ-101556143, JNJ-78278343, JNJ-87189401, Lutetium Lu-177 Vipivotide Tetraxetan
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Minneapolis, Minnesota + 10 more